US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Direxion Daily S&P Biotech Bull 3x Shares

142.74

-7.2700-4.85%

Post-market: 145.562.82+1.98%19:59 EDT

Volume:732.79K

Turnover:107.82M

Market Cap:467.40M

PE:- -

High:154.44

Open:148.70

Low:139.62

Close:150.01

52wk High:198.18

52wk Low:32.55

Shares:3.27M

Float Shares:3.27M

Volume Ratio:1.13

T/O Rate:22.38%

Dividend:1.34

Dividend Rate:0.94%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Anlon Healthcare Acquires Nearly 57% Stake in Bizotic Life Science

MT Newswires Live

Analysts Are Bullish on Top Healthcare Stocks: Scholar Rock Holding (SRRK), Summit Therapeutics (SMMT)

Press Release: Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST(TM) (etripamil) Nasal Spray for the Treatment of PSVT

Analysts Conflicted on These Healthcare Names: MoonLake Immunotherapeutics (MLTX), Solid Biosciences (SLDB) and Merck & Company (MRK)

Prestige Consumer to Acquire Breathe Right Brand Portfolio

Top 3 Health Care Stocks That Are Set To Fly In March

Buy Rating on TARA-002 Backed by Best-in-Class NMIBC Data, FDA-Aligned Phase 3 Strategy, and Solid Cash Runway

Health Care Roundup: Market Talk

Aster DM Healthcare Board to Consider Interim Dividend for Fiscal 2026

MT Newswires Live

Aurobindo Pharma's Unit Gets US FDA's Voluntary Action Indicated Classification; Shares Up 3%

MT Newswires Live

Regulatory Timing Risks Mount for Ovid Therapeutics as FDA Funding and Staffing Volatility Threaten Drug Approval Timelines

Samsung Electronics Signs Deal with KB Life, KB Golden Life Care to Boost Digital Healthcare for Seniors

MT Newswires Live

ASX Midday Sector Update: Healthcare Stocks Advance, Materials Struggle

MT Newswires Live

Analysts’ Opinions Are Mixed on These Healthcare Stocks: InflaRx (IFRX) and Kuros Biosciences (OtherCSBTF)

CurveBeam AI to Highlight WBCT and AI Imaging Solutions at NWR Healthcare Conference

Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity

Sigma Healthcare's New Bull Expects Profit Margins to Widen -- Market Talk

Alumis Plans FDA Filing for Plaque Psoriasis Drug After Positive Phase 3 Results

Novo Nordisk (0QIU) Receives a New Rating from Bernstein

Centessa’s ORX750 Poised as Potential Best-in-Class Orexin Agonist with Upcoming Phase 2a Catalyst and Favorable Risk–Reward

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/LABU/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LABU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","market":"US","secType":"STK","nameCN":"Direxion Daily S&P Biotech Bull 3x Shares","latestPrice":142.74,"timestamp":1774036800000,"preClose":150.01,"halted":0,"volume":732793,"hourTrading":{"tag":"盘后","latestPrice":145.56,"preClose":142.74,"latestTime":"19:59 EDT","volume":25411,"amount":3662385.6755,"timestamp":1774051171546,"change":2.82,"changeRate":0.019756,"amplitude":0.029985},"delay":0,"changeRate":-0.048463435770948485,"floatShares":3274486,"shares":3274486,"eps":0,"marketStatus":"Market Closed","change":-7.27,"latestTime":"03-20 16:00:00 EDT","open":148.7,"high":154.44,"low":139.6201,"amount":107823521.08857,"amplitude":0.098793,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":3,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774252800000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":150.01,"sharesOutstanding":3074486,"nav":142.609,"aum":488363498.63,"dividendRate":0.009353,"bidAskSpread":0.001672,"preHourTrading":{"tag":"盘前","latestPrice":149.08,"preClose":150.01,"latestTime":"09:29 EDT","volume":2670,"amount":395890.9659,"timestamp":1774013390002,"change":-0.93,"changeRate":-0.0062,"amplitude":0.028865},"postHourTrading":{"tag":"盘后","latestPrice":145.56,"preClose":142.74,"latestTime":"19:59 EDT","volume":25411,"amount":3662385.6755,"timestamp":1774051171546,"change":2.82,"changeRate":0.019756,"amplitude":0.029985},"volumeRatio":1.1267948044651654,"impliedVol":1.0281,"impliedVolPercentile":0.8486},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","floatShares":3274486,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.1267948044651654,"shares":3274486,"dividePrice":1.3351,"high":154.44,"amplitude":0.098793,"preClose":150.01,"low":139.6201,"week52Low":32.55,"pbRate":"--","week52High":198.18,"institutionHeld":0,"latestPrice":142.74,"eps":0,"divideRate":0.009353,"volume":732793,"delay":0,"ttmEps":0,"open":148.7,"prevYearClose":159.39,"prevWeekClose":148.85,"prevMonthClose":172.7,"prevQuarterClose":159.39,"fiveDayClose":148.85,"twentyDayClose":163.19,"sixtyDayClose":176.92},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LABU\",params:#limit:5,,,undefined,":[{"date":"2025-09-23","symbol":"LABU","amount":0.10273,"announcedDate":"2025-09-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-23","defaultRemindTime":1758634200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-30","payableDate":"2025-09-23","currency":"USD","dateTimestamp":1758600000000,"payDate":"2025-09-30"},{"date":"2025-06-24","symbol":"LABU","amount":0.21897,"announcedDate":"2025-06-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-24","defaultRemindTime":1750771800000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-01","payableDate":"2025-06-24","currency":"USD","dateTimestamp":1750737600000,"payDate":"2025-07-01"},{"date":"2025-03-25","symbol":"LABU","amount":0.10714,"announcedDate":"2025-03-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-25","defaultRemindTime":1742909400000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-25","currency":"USD","dateTimestamp":1742875200000,"payDate":"2025-04-01"},{"date":"2024-06-25","symbol":"LABU","amount":0.15021,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-25","defaultRemindTime":1719322200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-07-02","payableDate":"2024-06-25","currency":"USD","dateTimestamp":1719288000000,"payDate":"2024-07-02"},{"date":"2024-03-19","symbol":"LABU","amount":0.16064,"announcedDate":"2024-03-18","type":"dividend","market":"US","newRecordDate":"2024-03-20","defaultRemindTime":1710855000000,"name":"三倍做多标普生物-Direxion","recordDate":"2024-03-26","payableDate":"2024-03-20","currency":"USD","dateTimestamp":1710820800000,"payDate":"2024-03-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LABU\",market:\"US\",,,undefined,":[{"executeDate":"2018-06-19","recordDate":"2018-06-20","paymentDate":"2018-06-26","value":0.01932,"currency":"USD"},{"executeDate":"2018-09-25","recordDate":"2018-09-26","paymentDate":"2018-10-02","value":0.0954,"currency":"USD"},{"executeDate":"2018-12-27","recordDate":"2018-12-28","paymentDate":"2019-01-04","value":0.09621,"currency":"USD"},{"executeDate":"2019-03-19","recordDate":"2019-03-20","paymentDate":"2019-03-26","value":0.10973,"currency":"USD"},{"executeDate":"2019-06-25","recordDate":"2019-06-26","paymentDate":"2019-07-02","value":0.03745,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LABU\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LABU\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2620738404","title":"Anlon Healthcare Acquires Nearly 57% Stake in Bizotic Life Science","url":"https://stock-news.laohu8.com/highlight/detail?id=2620738404","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620738404?lang=en_us&edition=fundamental","pubTime":"2026-03-20 19:39","pubTimestamp":1774006773,"startTime":"0","endTime":"0","summary":"Anlon Healthcare (NSE:AHCL, BOM:544497) said it completed the acquisition of 56.67% equity in Bizotic Life Science on Friday, according to a same-day filing on Indian bourses.The acquisition makes Bizotic Life Science a subsidiary of Anlon Healthcare, the filing said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0128526141.USD","LU0029874061.USD","BK4581","XBI","BK4588","BK4137","BK4585","LABU","HCSG","XLV"],"gpt_icon":0},{"id":"2620738809","title":"Analysts Are Bullish on Top Healthcare Stocks: Scholar Rock Holding (SRRK), Summit Therapeutics (SMMT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620738809","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620738809?lang=en_us&edition=fundamental","pubTime":"2026-03-20 19:20","pubTimestamp":1774005609,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Scholar Rock Holding (SRRK), Summit Therapeutics (SM...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-scholar-rock-holding-srrk-summit-therapeutics-smmt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-scholar-rock-holding-srrk-summit-therapeutics-smmt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","BK4137","XBI","BLSX","LU0128526141.USD","LU0029874061.USD","LU2488822045.USD","SRRK","SMMT","BK4112","BLSG","BK4588","BK4139","BK4585","LABU"],"gpt_icon":0},{"id":"2620780220","title":"Press Release: Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST(TM) (etripamil) Nasal Spray for the Treatment of PSVT","url":"https://stock-news.laohu8.com/highlight/detail?id=2620780220","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620780220?lang=en_us&edition=fundamental","pubTime":"2026-03-20 19:12","pubTimestamp":1774005120,"startTime":"0","endTime":"0","summary":"-- FDA approval of CARDAMYST represents first new option in 30 years for the. -- Participants using CARDAMYST in clinical studies were 2x more likely to. convert symptomatic PSVT to sinus rhythm and did so more than 3x faster. -- CARDAMYST launch execution on track with positive initial engagement in. -- $200 million pro forma cash supports strong launch and operating runway. into late 2027; includes $106 million of cash at year-end and net. MONTREAL and CHARLOTTE, N.C., March 20, 2026  -- Milestone Pharmaceuticals Inc. , a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the fourth quarter and full year ending December 31, 2025, and provided corporate and regulatory updates. The main drivers of the fourth quarter and full year 2025 activities include the U.S. Food and Drug Administration  approval of CARDAMYST  nasal spray for the conversion of acute symptomatic episodes of paroxysma","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4081","BK4099","BK4232","MIST","BK4007","R","03160","BK4215","TM","EMA","BK4588","BK4555","BK4022","BK4585","BK4604","MAA","LABU"],"gpt_icon":0},{"id":"2620738388","title":"Analysts Conflicted on These Healthcare Names: MoonLake Immunotherapeutics (MLTX), Solid Biosciences (SLDB) and Merck & Company (MRK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620738388","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620738388?lang=en_us&edition=fundamental","pubTime":"2026-03-20 19:10","pubTimestamp":1774005007,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on MoonLake Immunotherapeutics (MLTX), Solid Biosciences (SLDB) and ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-moonlake-immunotherapeutics-mltx-solid-biosciences-sldb-and-merck-company-mrk-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-moonlake-immunotherapeutics-mltx-solid-biosciences-sldb-and-merck-company-mrk-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","SG9999015341.SGD","SLDB","LU1917777945.USD","XBI","LU0965509010.AUD","LU0266013472.USD","LU1430594728.SGD","MRK","SG9999014575.USD","LU0965508806.USD","LU1974910355.USD","IE00BSNM7G36.USD","LU0985320562.USD","SG9999013999.USD","IE00B4R5TH58.HKD","LU0868494617.USD","LU1989772923.USD","LU1934455863.HKD","SG9999014542.SGD","LU1162221912.USD","LU1571399168.USD","SG9999001176.USD","LU0211331839.USD","LU0122379950.USD","LU2125154778.USD","IE0002141913.USD","LU0648001328.SGD","LU1116320737.USD","LU2361044949.HKD","LU1066051498.USD","LU0477156953.USD","IE00BLSP4239.USD","HCSG","LU2361045086.USD","LU0029874061.USD","XLV","LU0106261372.USD","LU0965509101.SGD","LU0320765489.SGD","LU0965509283.SGD","LU1934455277.USD","LU1929549753.HKD","IE00BLSP4452.SGD","LU1983299246.USD","LU0432979614.USD","LABU","LU0265550946.USD","MLTX","BK4550"],"gpt_icon":0},{"id":"2620780628","title":"Prestige Consumer to Acquire Breathe Right Brand Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2620780628","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620780628?lang=en_us&edition=fundamental","pubTime":"2026-03-20 18:48","pubTimestamp":1774003724,"startTime":"0","endTime":"0","summary":"Prestige Consumer Healthcare ( ($PBH) ) has provided an announcement. On March 19, 2026, Prestige Brands, Inc., a wholly owned unit of Prestige Con...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/prestige-consumer-to-acquire-breathe-right-brand-portfolio?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/prestige-consumer-to-acquire-breathe-right-brand-portfolio?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","PBH","BK4581","XBI","LABU","XLV","BK4588","BK4585"],"gpt_icon":0},{"id":"2620464787","title":"Top 3 Health Care Stocks That Are Set To Fly In March","url":"https://stock-news.laohu8.com/highlight/detail?id=2620464787","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620464787?lang=en_us&edition=fundamental","pubTime":"2026-03-20 18:23","pubTimestamp":1774002180,"startTime":"0","endTime":"0","summary":"Opportunity to buy undervalued health care stocks. RSI is a momentum indicator that compares strength on up and down days. Here's a list of oversold stocks with RSI near or below 30.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/20/Healthcare-stocks.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/20/Healthcare-stocks.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/trading-ideas/long-ideas/26/03/51373991/top-3-health-care-stocks-that-are-set-to-fly-in-march","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/long-ideas/26/03/51373991/top-3-health-care-stocks-that-are-set-to-fly-in-march","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["XLV","LABU","BK4585","BK4588","XBI","BK4581"],"gpt_icon":0},{"id":"2620799782","title":"Buy Rating on TARA-002 Backed by Best-in-Class NMIBC Data, FDA-Aligned Phase 3 Strategy, and Solid Cash Runway","url":"https://stock-news.laohu8.com/highlight/detail?id=2620799782","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620799782?lang=en_us&edition=fundamental","pubTime":"2026-03-20 18:15","pubTimestamp":1774001741,"startTime":"0","endTime":"0","summary":"Analyst Charles Zhu of LifeSci Capital maintained a Buy rating on Protara Therapeutics, retaining the price target of $26.00. Charles Zhu has given...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-on-tara-002-backed-by-best-in-class-nmibc-data-fda-aligned-phase-3-strategy-and-solid-cash-runway-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-on-tara-002-backed-by-best-in-class-nmibc-data-fda-aligned-phase-3-strategy-and-solid-cash-runway-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","TARA"],"gpt_icon":0},{"id":"2620786391","title":"Health Care Roundup: Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2620786391","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620786391?lang=en_us&edition=fundamental","pubTime":"2026-03-20 16:20","pubTimestamp":1773994800,"startTime":"0","endTime":"0","summary":"The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.0655 GMT - Chularat Hospital faces a revenue hit in 2026 from Middle East tensions, CGS International's Kasem Prunratanamala says in a research report. At an analyst meeting, management expressed caution over its outlook owing to these tensions, noting potential spillover to Thailand's economy and domestic patient traffic. The Thai hospital's inpatient revenues are likely to fall 5% this year, the analyst estimates. The brokerage cuts its 2026 revenue growth forecast for the hospital to 1% from 4%, and lowers the stock's target price to THB1.95 from THB2.04. However, CGS International maintains the stock's add rating, supported by expected earnings recovery for the hospital in 2027-2028. Shares are 1.4% higher at THB1.45. ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","XBI","LABU","H02.SI","BK6079","SG9999006266.SGD","BK4588","BK6506","BK4585","XLV","IE0031814969.USD"],"gpt_icon":0},{"id":"2620785500","title":"Aster DM Healthcare Board to Consider Interim Dividend for Fiscal 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2620785500","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620785500?lang=en_us&edition=fundamental","pubTime":"2026-03-20 15:58","pubTimestamp":1773993533,"startTime":"0","endTime":"0","summary":"Aster DM Healthcare  said its board of directors will meet on March 26 to consider the declaration of an interim dividend for the fiscal year ending March 31, according to a filing with the Indian bourses on Friday.If approved, the record date for determining shareholder eligibility for the dividend will be April 3.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HCSG","VIG","BK4585","LU0128526141.USD","XBI","BK4581","LU0029874061.USD","BK4161","BK4588","DM","BK4546","BK4137","LABU","XLV"],"gpt_icon":0},{"id":"2620767207","title":"Aurobindo Pharma's Unit Gets US FDA's Voluntary Action Indicated Classification; Shares Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620767207","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620767207?lang=en_us&edition=fundamental","pubTime":"2026-03-20 14:19","pubTimestamp":1773987572,"startTime":"0","endTime":"0","summary":"Aurobindo Pharma  said Unit-V of its wholly-owned subsidiary, Apitoria Pharma, has been classified as \"voluntary action indicated\" by the U.S. Food and Drug Administration , according to a Friday filing to the Indian stock exchanges.The US FDA inspected the facility, based in the Sangareddy district of Telangana, India, between Dec. 1, 2025, and Dec. 12, 2025.At the end of the inspection, the regulator issued a 'Form 483' with three observations.The unit has now received an establishment inspection report classifying the facility as 'voluntary action indicated', marking the inspection as closed.The company's shares were up nearly 3% in recent trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","LABU","BK4588"],"gpt_icon":0},{"id":"2620207715","title":"Regulatory Timing Risks Mount for Ovid Therapeutics as FDA Funding and Staffing Volatility Threaten Drug Approval Timelines","url":"https://stock-news.laohu8.com/highlight/detail?id=2620207715","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620207715?lang=en_us&edition=fundamental","pubTime":"2026-03-20 14:00","pubTimestamp":1773986436,"startTime":"0","endTime":"0","summary":"Ovid Therapeutics (OVID) has disclosed a new risk, in the Taxation & Government Incentives category. Ovid Therapeutics faces heightened regulatory ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/regulatory-timing-risks-mount-for-ovid-therapeutics-as-fda-funding-and-staffing-volatility-threaten-drug-approval-timelines?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/regulatory-timing-risks-mount-for-ovid-therapeutics-as-fda-funding-and-staffing-volatility-threaten-drug-approval-timelines?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","BK4007","BK4588","OVID","LABU","BK4539","BK4585"],"gpt_icon":0},{"id":"2620095832","title":"Samsung Electronics Signs Deal with KB Life, KB Golden Life Care to Boost Digital Healthcare for Seniors","url":"https://stock-news.laohu8.com/highlight/detail?id=2620095832","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620095832?lang=en_us&edition=fundamental","pubTime":"2026-03-20 11:03","pubTimestamp":1773975811,"startTime":"0","endTime":"0","summary":"Samsung Electronics  signed a memorandum of understanding with KB Financial Group  affiliate KB Life and KB Golden Life Care to advance digital healthcare services for seniors, the electronics products maker said in a Friday release.The partnership brings together Samsung Electronics' technology with KB Life's senior care expertise and KB Golden Life Care's operational experience to develop wearable health services, AI appliances, and SmartThings Pro-based residential solutions for seniors, the release said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4207","LU0029874061.USD","XLV","BK4588","KB","BK4581","LABU","XBI","LU0128526141.USD","HCSG","BK4585","BK4137"],"gpt_icon":0},{"id":"2620205261","title":"ASX Midday Sector Update: Healthcare Stocks Advance, Materials Struggle","url":"https://stock-news.laohu8.com/highlight/detail?id=2620205261","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620205261?lang=en_us&edition=fundamental","pubTime":"2026-03-20 10:08","pubTimestamp":1773972508,"startTime":"0","endTime":"0","summary":"Healthcare stocks advanced 1% at midday Friday.CSL (ASX:CSL) gained 1% in recent trade.Meanwhile, materials stocks struggled, shedding nearly 2%.BHP Group (ASX:BHP) shares fell almost 2% in recent trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7507","BK4581","BK4137","LU0029874061.USD","ARKG","BK7095","BK7067","BHP.AU","XLV","BK7511","XBI","LU0128526141.USD","CSL.AU","BK4585","HCSG","BK7508","BK7501","BK4544","BK4588","LABU"],"gpt_icon":0},{"id":"2620205141","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: InflaRx (IFRX) and Kuros Biosciences (OtherCSBTF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620205141","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620205141?lang=en_us&edition=fundamental","pubTime":"2026-03-20 09:40","pubTimestamp":1773970808,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on InflaRx (IFRX) and Kuros Biosciences (CSBTF). InflaRx (IFRX) Life...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-inflarx-ifrx-and-kuros-biosciences-othercsbtf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-inflarx-ifrx-and-kuros-biosciences-othercsbtf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","BK4581","BK4139","XBI","LU0029874061.USD","XLV","IFRX","BK4588","BK4585","HCSG","CSBTF","LABU","LU0128526141.USD"],"gpt_icon":0},{"id":"2620272429","title":"CurveBeam AI to Highlight WBCT and AI Imaging Solutions at NWR Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2620272429","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620272429?lang=en_us&edition=fundamental","pubTime":"2026-03-20 06:41","pubTimestamp":1773960118,"startTime":"0","endTime":"0","summary":"Curvebeam AI Ltd. ( ($AU:CVB) ) has issued an announcement. CurveBeam AI will showcase its point-of-care weight-bearing CT imaging systems and AI-d...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/curvebeam-ai-to-highlight-wbct-and-ai-imaging-solutions-at-nwr-healthcare-conference?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/curvebeam-ai-to-highlight-wbct-and-ai-imaging-solutions-at-nwr-healthcare-conference?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","BK4551","BK4581","BK4543","XBI","BK4587","LU0029874061.USD","XLV","AIYY","BK4588","BK4585","HCSG","LABU","AI","BK4023","BK4528","LU0128526141.USD"],"gpt_icon":0},{"id":"2620627296","title":"Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity","url":"https://stock-news.laohu8.com/highlight/detail?id=2620627296","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620627296?lang=en_us&edition=fundamental","pubTime":"2026-03-20 06:30","pubTimestamp":1773959400,"startTime":"0","endTime":"0","summary":"David Meeker Quote   David Meeker Quote   Dr. Shoemaker quote   Dr. Shoemaker quote   IMCIVREE packaging   IMCIVREE packaging with vial   IMCIVREE 3D Render   IMCIVREE 3D Render  -- First and only FDA","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/19/3259502/0/en/Rhythm-Pharmaceuticals-Announces-FDA-Approval-of-IMCIVREE-setmelanotide-for-Patients-with-Acquired-Hypothalamic-Obesity.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK4157","VUS","BMI","AVP","EC","BK4201","LABU"],"gpt_icon":0},{"id":"2620264274","title":"Sigma Healthcare's New Bull Expects Profit Margins to Widen -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2620264274","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620264274?lang=en_us&edition=fundamental","pubTime":"2026-03-20 06:06","pubTimestamp":1773957960,"startTime":"0","endTime":"0","summary":"2206 GMT - Sigma Healthcare's share price recently dropped to a more than one-year low, leading Jefferies to turn bullish on the pharmacy owner's stock. Analyst David Stanton says Sigma is a high-quality retail franchise. \"We expect growth to continue, notwithstanding moderating impact from GLP-1 sales in 2H FY26,\" Jefferies says. It expects Sigma's profit margins to expand more. That's due to increased volumes off a fixed-cost base and ongoing growth in higher-margin generic drugs. Jefferies also expects Sigma to make improvements in its wholesaling business. It upgrades Sigma to buy, from hold. Sigma ended Thursday at A$2.66, below Jefferies's A$3.05/share price target. ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4581","LU0128526141.USD","SIG.AU","HCSG","XBI","XLV","BK4137","LU0029874061.USD","LABU","BK7103","BK4585"],"gpt_icon":0},{"id":"2620714082","title":"Alumis Plans FDA Filing for Plaque Psoriasis Drug After Positive Phase 3 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2620714082","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620714082?lang=en_us&edition=fundamental","pubTime":"2026-03-20 05:16","pubTimestamp":1773954960,"startTime":"0","endTime":"0","summary":"Alumis plans to seek Food and Drug Administration approval in the later this year for its lead drug candidate after reporting positive late-stage trial results.The disclosure comes as the biotechnology company on Thursday said it narrowed its loss last year and strengthened its balance sheet with a recent equity raise.Alumis said its drug, envudeucitinib, met all primary and secondary endpoints in two Phase 3 trials in patients with moderate-to-severe plaque psoriasis. About 65% of patients achieved near-complete skin clearance and more than 40% achieved complete clearance at 24 weeks, with a safety profile consistent with earlier studies.The company said it intends to submit a new-drug application to the FDA in the second half of this year, and that it will present additional data from the trials later this month at a dermatology conference.Alumis is also studying the drug in systemic lupus erythematosus, with midstage data expected in the third quarter.Separately, the company said it","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","LABU","ALMS","BK4007"],"gpt_icon":0},{"id":"2620293279","title":"Novo Nordisk (0QIU) Receives a New Rating from Bernstein","url":"https://stock-news.laohu8.com/highlight/detail?id=2620293279","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620293279?lang=en_us&edition=fundamental","pubTime":"2026-03-20 04:35","pubTimestamp":1773952559,"startTime":"0","endTime":"0","summary":"Novo Nordisk received a Sell rating and price target from Bernstein analyst Justin Smith today. Smith covers the Healthcare sector, focusing on sto...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/novo-nordisk-0qiu-receives-a-new-rating-from-bernstein-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/novo-nordisk-0qiu-receives-a-new-rating-from-bernstein-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NVOH","NVOX","LU1093756168.USD","LU1093756325.SGD","IE00BKVL7J92.USD","LU0154236417.USD","XBI","BK4581","NVO","BK4532","BK4588","BK4585","BK4599","LABU","BK4007","IE00BZ1G4Q59.USD"],"gpt_icon":0},{"id":"2620275273","title":"Centessa’s ORX750 Poised as Potential Best-in-Class Orexin Agonist with Upcoming Phase 2a Catalyst and Favorable Risk–Reward","url":"https://stock-news.laohu8.com/highlight/detail?id=2620275273","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620275273?lang=en_us&edition=fundamental","pubTime":"2026-03-20 03:35","pubTimestamp":1773948917,"startTime":"0","endTime":"0","summary":"Centessa Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Francois Brisebois from LifeSci Capi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/centessas-orx750-poised-as-potential-best-in-class-orexin-agonist-with-upcoming-phase-2a-catalyst-and-favorable-risk-reward-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/centessas-orx750-poised-as-potential-best-in-class-orexin-agonist-with-upcoming-phase-2a-catalyst-and-favorable-risk-reward-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLV","XBI","BK4581","BK4588","BK4585","LABU"],"gpt_icon":0}],"pageSize":20,"totalPage":23,"pageCount":3,"totalSize":444,"code":"91000000","status":"200"}]}}